--- title: "NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin" ocid: "ocds-h6vhtk-028c7b" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-028c7b" markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-028c7b.md" json_url: "https://d3tenders.com/contract/ocds-h6vhtk-028c7b.json" source: "Find A Tender Service" current_stage: "Award" buyer: "NHS ENGLAND" published: "2024-12-16" --- # NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin Buyer: NHS ENGLAND Current stage: Award OCID: ocds-h6vhtk-028c7b [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-028c7b) [Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-028c7b.json) ## Summary NHS England has announced an extension and modification of their NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework agreement, originally commencing on July 1st, 2021, and set to end on March 31st, 2025, has been extended by 3 months for IVIg products (Lots 1, 2, 5, and 6) until September 30th, 2025, and by 6 months for SCIg products (Lots 3 and 7) until December 31st, 2025. This adjustment aligns with ongoing efforts to transition patients from products supplied by certain suppliers not secured under a new framework to those guaranteed by new suppliers. Additionally, the estimated value of the framework agreement is being increased from £1.2bn to £1.6bn, reflecting higher demand and price adjustments due to inflation and rebate schemes. This tender creates substantial opportunities for suppliers within the pharmaceutical industry, particularly those specialising in immunoglobulin products. Companies capable of ensuring continuous supply and managing product transitions will find this an advantageous proposition. Both large enterprises and SMEs with robust supply chain capabilities are well-suited to compete, especially amid the increased framework value and extension, which highlights NHS England’s reliance on reliable pharmaceutical partners to ensure the uninterrupted supply of critical immunoglobulin products to healthcare providers. ## Notice National Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points. ### Lot Information Lot No: 1-9 NHS Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points. Lot 1 - 5% Intravenous Immunoglobulin (5% IVIg) This modification notice is to provide notice of the modification of the framework agreement (as defined below) to (i) extend its duration with a limited number of suppliers and (ii) increase the estimated value of the framework agreement across all lots. The modification is further described in sections VII.2.1 and VII.2.2 below, but in short NHS England were required to (i) modify the Current Framework with the Absent Suppliers (as defined below) so as to extend the Current Framework for those Absent Products (as defined below) for a further period of (i) 3-months for IVIg products (Lots 1, 2, 5 and 6) (so to 30th September 2025) and (ii) 6-months for SCIg products (Lots 3 and 7) (so to 31st December 2025) and (ii) increase the estimated value of the Current Framework from PS1.2bn to PS1.6bn (an increase of 33%). Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months Lot 2: 10% Intravenous Immunoglobulin (10% IVIg) 10% Intravenous Immunoglobulin (10% IVIg) Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months Lot 3: Subcutaneous Immunoglobulin (SCIg) Subcutaneous Immunoglobulin (SCIg) Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months Lot 4: Facilitated Subcutaneous Immunoglobulin (fSCIg) Facilitated Subcutaneous Immunoglobulin (fSCIg) Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months Lot 6: 10% Intravenous Immunoglobulin (10% IVIg) 10% Intravenous Immunoglobulin (10% IVIg) Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months Lot 5: 5% Intravenous Immunoglobulin (5% IVIg) 5: 5% Intravenous Immunoglobulin (5% IVIg) Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months Lot 7: Subcutaneous Immunoglobulin (SCIg) Subcutaneous Immunoglobulin (SCIg) Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months Lot 9: Anti-D Immunoglobulin (Anti-D) Anti-D Immunoglobulin (Anti-D) Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months Lot 8: Facilitated Subcutaneous Immunoglobulin (fSCIg) Facilitated Subcutaneous Immunoglobulin (fSCIg) Options: option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months ## Key Details | Field | Value | | --- | --- | | Publication source | Find A Tender Service | | Latest notice | https://www.find-tender.service.gov.uk/Notice/040406-2024 | | Notice type | Tender Notice | | Procurement type | Framework | | Procurement category | Goods | | Procurement method | Open | | Procurement method details | Open procedure | | Tender suitability | Not specified | | Awardee scale | Large, SME | | All stages | Tender, Award | ## Dates | Field | Value | | --- | --- | | Publication date | 16 Dec 2024 | | Submission deadline | 26 Feb 2021 | | Future notice date | Not specified | | Award date | 22 Jun 2021 | | Contract period | 30 Jun 2021 - 31 Mar 2025 | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £1,200,000,000 | | Lots value | Not specified | | Awards value | Not specified | | Contracts value | £1,600,000,001 | ## Status | Field | Value | | --- | --- | | Tender status | Complete | | Lots status | Active, Cancelled | | Awards status | Active | | Contracts status | Active | ## Buyer | Field | Value | | --- | --- | | Main buyer | NHS ENGLAND | | Additional buyers | THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND) | | Locality | RUNCORN | | Post town | Warrington | | Postcode | WA7 2ES | | Country | England | | ITL 1 | TLI London | | ITL 2 | TLI4 Inner London - East | | ITL 3 | TLI45 Lambeth | | Local authority | Lambeth | | Electoral ward | Waterloo & South Bank | | Westminster constituency | Vauxhall and Camberwell Green | | Delivery location | Not specified | ## Supplier | Field | Value | | --- | --- | | Number of suppliers | 7 | | Supplier names | BIO PRODUCTS LABORATORY; BIOTEST; CSL BEHRING; GRIFOLS; LFB; OCTAPHARMA; SHIRE PHARMACEUTICALS | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33651520 - Immunoglobulins ## Release History - 16 Dec 2024 at 11:04 - AwardUpdate - Award Notice - https://www.find-tender.service.gov.uk/Notice/040406-2024 - 16 Dec 2024 at 11:03 - AwardUpdate - Award Notice - https://www.find-tender.service.gov.uk/Notice/040405-2024 - 16 Dec 2024 at 11:02 - AwardUpdate - Award Notice - https://www.find-tender.service.gov.uk/Notice/040404-2024 - 16 Dec 2024 at 11:01 - AwardUpdate - Award Notice - https://www.find-tender.service.gov.uk/Notice/040403-2024 - 16 Dec 2024 at 11:00 - AwardUpdate - Award Notice - https://www.find-tender.service.gov.uk/Notice/040401-2024 - 16 Dec 2024 at 10:59 - AwardUpdate - Award Notice - https://www.find-tender.service.gov.uk/Notice/040400-2024 - 16 Dec 2024 at 10:58 - AwardUpdate - Award Notice - https://www.find-tender.service.gov.uk/Notice/040399-2024 - 16 Dec 2024 at 10:56 - AwardUpdate - Award Notice - https://www.find-tender.service.gov.uk/Notice/040398-2024 - 16 Dec 2024 at 10:50 - AwardUpdate - Award Notice - https://www.find-tender.service.gov.uk/Notice/040395-2024 - 13 Dec 2024 at 15:44 - AwardUpdate - Award Notice - https://www.find-tender.service.gov.uk/Notice/040318-2024 - 22 Jul 2021 at 15:00 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/017380-2021 - 22 Jan 2021 at 11:50 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/001317-2021 ## Notice URLs - http://health.atamis.co.uk - http://www.bpl.co.uk - https://www.england.nhs.uk/ - https://www.gov.uk/courts-tribunals - https://www.judiciary.uk/courts-and-tribunals/high-court/ ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-028c7b. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-028c7b.json.